IngredientsButyric acid, also known under the systematic name butanoic acid, is a straight-chain alkyl fatty acid with the chemical formula CH3CH2CH2COOH. Its other chemical names include n-butyric acid, n-butanoic acid, and propylformic acid. Its common name derives from the Ancient Greek word ÎČÎżÏÏῥÏÎżÎœ, meaning "butter," the substance in which it was first identified. It is an oily, colorless liquid with an unpleasant odor. Salts and esters of butyric acid are known as butyrates or butanoates.
Butyric acid is one of three common short-chain fatty acids (SCFAs) in the human gut, alongside acetic acid and propionic acid, which together make up 90â95% of the SCFAs in the colon. Butyrate typically constitutes up to 20% of total SCFA in the human colon, with absolute concentrations above 10 mM in human feces.
The free acid does not occur widely in nature, but its esters are widespread. Butyric acid is found in plant oils and animal fats, especially products such as butter, ghee, and raw milk. However, the amount of butyric acid found in foods like butter and ghee is small compared to the amount that is made in the gut. Butyric acid makes up about 3â4% of butter. Butter is one of the best dietary sources of butyric acid: about 11% of the saturated fat in butter comes from SCFAs, and butyric acid makes up about half of these SCFAs. Parmesan cheese is also a recognized food source, as are fermented dairy products.
The body makes most of its butyrate in the colon when bacteria ferment dietary fiber and resistant starch. The key producers are beneficial species including Faecalibacterium prausnitzii, Roseburia, and Eubacterium rectale. Resistant starchârich foods such as cooked-and-cooled potatoes, rice, and legumes substantially increase luminal butyrate concentrations compared with lower-fermentability fibres. Soluble fibres found in oats, barley ÎČ-glucans, pectin-rich fruits (apples, citrus), and guar gum similarly enhance microbial butyrate formation.
Butyric acid was first observed in an impure form in 1814 by the French chemist Michel EugĂšne Chevreul. By 1818, he had purified it sufficiently to characterize it. It was by the acidification of animal fat soaps that Chevreul was able to identify butyric acid along with several other fatty acids for the first time, including oleic acid and valeric acid.
Because butyric acid as a discrete chemical entity was not isolated until the 19th century, no traditional medical system used it explicitly by that name. However, the foods richest in butyric acidâparticularly ghee and fermented dairyâwere central to several ancient medical traditions, and modern science has since attributed some of their historically ascribed digestive properties in part to butyric acid content.
Ghee has a rich history dating back over 5,000 years, with roots in ancient India. It has been an integral part of Ayurvedic medicine and Indian cuisine, revered for its medicinal and culinary properties, and has since spread to other parts of the world, becoming a staple in Middle Eastern, North African, and Southeast Asian cuisines. Ancient texts, like the Vedas, mention ghee in various contexts, highlighting its importance in daily diets and ceremonial practices. Ghee, or clarified butter, was not only used as a culinary ingredient but also held deep spiritual and symbolic meaning in ancient Indian traditions. Historically, ancient civilizations used ghee not just for cooking but also for medicinal purposes; it was believed to help in wound healing and to soothe burns when applied topically.
In Ayurveda, ghee was traditionally prepared from cultured or fermented cream. Research shows that lactic acid bacteria, which convert lactose to lactate, also convert lactate into butyric acid, making the two fermentations used in the traditional ghee-making process a butyric acidâgenerating pathway. While Ayurvedic texts attributed ghee's digestive and anti-inflammatory benefits to the whole preparation, the butyric acid fraction is now recognized as one of its biologically active components.
Throughout human history, fermented foodsâincluding aged cheeses (Parmesan, pecorino), fermented milks, and certain fermented vegetablesâhave been dietary staples across European, Middle Eastern, and East Asian cultures. These foods inherently contain butyric acid as a product of microbial fermentation, though no traditional system framed their use in terms of butyrate specifically. The attribution of gut-supportive properties to such foods preceded by millennia the isolation and characterization of butyric acid itself.
Unlike multi-constituent botanical supplements, butyric acid is itself the primary active molecule. Its biological activity is mediated through several distinct, well-characterized molecular pathways.
Butyric acid provides approximately 70% of colon cells' total energy needs. The fate of cytoplasmic butyrate depends on the cell's state of differentiation; in differentiated colonocytes, butyrate is rapidly oxidized and utilized for cellular energy production. This oxidative metabolism is the dominant fate of butyrate in healthy colonic epithelial cells and is essential for their survival, proliferation, and barrier maintenance.
As early as 1977, butyric acid was discovered as an endogenous inhibitor of HDAC. It can inhibit ZnÂČâș-dependent class I (HDAC1, HDAC2, HDAC3, and HDAC8) and class II (HDAC4, HDAC5, HDAC7, HDAC9, HDAC6, and HDAC10) HDACs, and thereby regulate inflammation and adaptive immunity. At a cellular level, butyrate exerts beneficial effects through the inhibition of HDAC enzymes, leading to increased acetylation of histones and more relaxed chromatin structure, which in turn improves gene accessibility to aid transcription. This action as an HDAC inhibitor is critical for several cellular processes, including cell growth, differentiation, and apoptosis.
The median inhibitory concentration required to inhibit HDAC activity was measured to be 223 ± 64 Όmol/L for propionate, whereas for butyrate it was found to be 52 ± 11 Όmol/L, indicating that butyrate is a more potent HDAC inhibitor at lower concentrations than other common SCFAs.
Butyrate is a histone deacetylase inhibitor and also signals through three G-protein coupled receptors. Butyrate activates the GPR109a receptor to suppress colonic inflammation and carcinogenesis; GPR109a signaling promotes anti-inflammatory properties in colonic macrophages and dendritic cells and enables differentiation of regulatory T cells (Treg) and IL-10-producing T cells. Among short-chain fatty acids, only butyric acid activates GPR109A with a low threshold.
Butyrate's inhibition of HDAC enzymes is at the center of its anti-inflammatory activity. Through this HDAC inhibitor activity, butyrate suppresses the production of pro-inflammatory cytokines such as interferon-Îł, tumor necrosis factor-alpha, interleukin-6, and interleukin-8 and promotes the production of the anti-inflammatory factor interleukin-10. These actions are demonstrated to occur through the modulation of transcription factors such as NF-ÎșB and STAT3.
Experimental studies demonstrate that butyrate supports colonocyte energy metabolism, strengthens tight-junction integrity, enhances mucin and antimicrobial peptide production, and promotes epithelial repair. These effects are mediated through immunomodulatory pathways, in particular involving G-proteinâcoupled receptor activation and histone deacetylase inhibition.
A growing body of evidence indicates that butyrate can inhibit neoplastic transformation in colonic epithelial cells. This effect is primarily mediated through HDAC inhibition, leading to activation of tumor suppressor genes and induction of apoptosis in cancer cells. These actions contribute to cell-cycle arrest and limit the proliferation of dysplastic cells. This phenomenon is known as the "butyrate paradox": butyrate supports physiological proliferation and regeneration of normal colonocytes, yet in dysplastic or malignant cells it activates epigenetic pathways that suppress their growth.
The mechanistic explanation for this paradox lies in cellular metabolism: colon cancer cells preferentially use glucose rather than SCFA as fuelâan adaptation referred to as the Warburg effect. The dominance of glycolytic metabolism over oxidative phosphorylation in cancerous colonocytes allows butyrate to accumulate and act as an HDAC inhibitor, thereby halting cell cycle progression through altered gene expression. At low doses, butyrate is oxidized by the mitochondria, activating histone acetyltransferases (HATs), while at higher doses (concentrations saturating ÎČ-oxidation), butyrate's HDAC inhibition activity becomes more relevant.
The biosynthesis of butyrate in the gut occurs via two metabolic pathways: the first involves the phosphorylation of butyryl-CoA to butyryl-phosphate and then transformation to butyrate via the enzyme butyrate kinase; the second involves the transformation of butyryl-CoA to acetate and then to butyric acid.
Background and rationale: IBD is commonly associated with intestinal dysbiosis characterized by depletion of butyrogenic bacteria. This leads to a functionally relevant butyrate deficiency that contributes to epithelial barrier dysfunction, immune dysregulation, and persistent mucosal inflammation. Patients with active UCâparticularly those with high disease activityâhave been found to have significantly lower butyrate levels compared with individuals in remission and healthy controls.
Ulcerative colitis â clinical evidence:
IBD overall evidence strength: Clinically, sodium butyrate has shown therapeutic potential primarily in ulcerative colitis, with more limited data in Crohn's disease. Evidence from oral microencapsulated forms is increasingly positive but largely comes from small and/or non-blinded studies. Larger, properly powered RCTs are still needed.
A multi-center cross-sectional study assessed the effectiveness of sodium butyrate in a triglyceride matrix in patients with IBS. A total of 3,000 patients with confirmed IBS were enrolled, and they were treated with sodium butyrate at a dosage of 150 mg twice daily for 12 weeks. A statistically significant improvement in severity of abdominal pain was observed (p < 0.001). Moreover, flatulence, diarrhea, constipation, urgent pressure for bowel movements, nausea, and vomiting decreased significantly (p < 0.001). This was a large prospective trial, but its cross-sectional and non-blinded design limits causal interpretation.
In an earlier clinical study on IBS examining butyric acid supplementation, researchers reported no side effects at a dose of 300 mg per day. Some research suggests that butyric acid supplements could potentially be used as a treatment for IBS and Crohn's disease, though evidence remains preliminary.
Butyrate, the four-carbon fatty acid formed in the human colon by bacterial fermentation of carbohydrates, putatively suppresses colorectal cancer (CRC). Butyrate has diverse and apparently paradoxical effects on cellular proliferation, apoptosis, and differentiation that may be either pro-neoplastic or anti-neoplastic, depending upon factors such as the level of exposure, availability of other metabolic substrate, and the intracellular milieu.
In humans, the relationship between luminal butyrate exposure and CRC has been examined only indirectly in case-control studies, by measuring fecal butyrate concentrations, although this may not accurately reflect effective butyrate exposure during carcinogenesis. Results of these investigations have been mutually contradictory.
At least two studies have reported that colorectal cancer cases have fewer butyrate-producing bacteria. Butyrate can also inhibit glycolysis and tumor growth by blocking glucose metabolism in CRC and lowering metabolic precursors and energy supply. Treatment with butyrate on human cancer cell lines has been demonstrated to induce apoptosis and modulate Bcl-2 family protein expression.
Evidence strength: Mechanistic and animal model evidence is extensive, and epidemiological data (higher fiber intake correlating with lower CRC risk) is consistent with a role for butyrate. However, direct interventional human evidence for butyrate supplementation preventing or treating CRC is lacking. This remains an active area of research, and no clinical recommendations for butyrate as a CRC treatment exist.
Emerging data suggest that butyrate is a health-promoting molecule able to modulate energy homeostasis, insulin sensitivity, lipid metabolism, and inflammation. A deficiency of butyrate has been linked to deleterious effects on human metabolism and has been reported in individuals with obesity.
In a randomized clinical trial including 54 children with obesity, a 40% absolute increase in the rate of children experiencing a decrease of at least 0.25 SD scores of body mass index was observed at 6 months in those treated with butyrate compared with those receiving placebo in an intention-to-treat analysis. Adverse effects included transient mild nausea and headache reported by 2 patients during the first month of butyrate intervention. The findings suggest that oral butyrate supplementation may be effective in the treatment of pediatric obesity.
A study in Italy among 46 overweight or obese adults following a low-calorie diet showed that taking 625 mg of sodium butyrate three times daily (total daily dose: 1,875 mg) for 12 weeks did not result in greater loss of fat compared to placebo overall. Further analysis, however, showed that those without type 2 diabetes had a greater reduction in body weight than those given placebo.
Early animal studies have shown that increasing dietary fiber intake may improve insulin sensitivity and lower the risk of obesity. However, at this point, there is limited evidence to suggest that increasing butyric acid in humans has the same effect on insulin sensitivity.
Butyrate, a gut microbiota metabolite, has been reported to have hepato-protective effects in NAFLD animal models. According to a systematic review, butyrate contributes to a wide variety of biological processes in the gut-liver axis, with beneficial properties including improving intestinal homeostasis and liver health as well as anti-inflammatory, metabolism-regulatory, and anti-oxidative effects. As of current review, this evidence is primarily derived from animal studies and mechanistic analyses; large-scale interventional human trials in NAFLD are ongoing.
Butyrate is instrumental in maintaining intestinal barrier function and immune homeostasis and exhibits notable anti-inflammatory, antioxidant, and metabolic regulatory potentials in cardiovascular diseases. Findings indicate that butyrate can influence cardiovascular health through multiple pathways, including the modulation of G protein-coupled receptors (GPCRs), histone deacetylases (HDACs), and peroxisome proliferator-activated receptors (PPARs). Research has also suggested that butyrate may have an effect against hypertension, and one study found that higher fecal butyrate levels were inversely associated with hypertension in overweight and obese cancer survivors, with increases in butyrate over a year linked to lower blood pressure. These cardiovascular associations are largely observational and/or mechanistic; prospective human interventional evidence is lacking.
Current research recognizes butyrate as a growing modulator of neurological health via its interaction with the gut-brain axis. Butyrate's neuroprotective effects are mediated through activation of specific G-proteinâcoupled receptors, such as FFAR3 and GPR109a, and inhibition of HDACs.
Butyrate is thought to influence the gut-brain axis, potentially by enhancing colonic serotonin production, a key neurotransmitter involved in mood and behavior regulation. Animal studies suggest that butyrate may exert antidepressant-like effects by stimulating the production of brain-derived neurotrophic factor (BDNF), a protein essential for neuronal development and survival.
In multiple models of Huntington's disease, sodium butyrate (NaB) and phenylbutyrate, a structurally similar analog, have been shown to rescue histone acetylation, prevent neuronal cell death, and extend the lifespan of mice.
Sodium butyrate can regulate gut microbiota and improve brain functioning in neurological disorders. However, butyrate's role in Parkinson's disease is complex, and further studies are needed to explain whether the butyrate concentration is associated with the onset of PD and its severity. Fourteen individuals with Parkinson's disease and three normal controls completed a 30-day dietary tributyrin supplementation study (500 mg taken orally three times daily), demonstrating a reassuring safety profile.
Evidence strength: Neurological evidence is predominantly preclinical (animal models, cell lines). Human interventional trials are in their earliest stages. The gut-brain axis hypothesis is scientifically plausible but not yet established by controlled human trials of butyrate.
A 2020 study examined the use of butyric acid supplements to treat and prevent digestive tract disorders, including diarrhea, irritable bowel syndrome, diverticulitis, and post-surgical conditions. Evidence in these areas is primarily from small, uncontrolled, or observational studies. High-quality RCT data is sparse.
Butyrate supplements come in a few different forms, most commonly sodium butyrate and calcium-magnesium ("cal-mag") butyrate. These supplements deliver butyrate bound to sodium or to calcium and magnesium. Coated butyrate tablets also exist, in which butyrate "beads" are protected by a layer of fatty acids; in theory, the fatty coating should prevent the release of butyrate before it reaches the intestine.
Tributyrin is a distinct pro-drug form: Tributyrin, naturally present in butter, is a neutral SCFA triglyceride. It is rapidly absorbed and stable in plasma, and diffuses through cell and organelle membranes, where it is metabolized by intracellular lipases, releasing butyrate within cells. Tributyrin has more favorable pharmacokinetics than sodium butyrate and is well tolerated; liquid tributyrin filled into gelatin capsules and administered orally results in millimolar concentrations of butyrate both in plasma and inside the cell.
Microencapsulated sodium butyrate (MSB) is designed to be colon-targeted. Microencapsulated sodium butyrate is described as a colon-targeted form of butyric acid with anti-inflammatory and mucosal healing properties.
Studies performed using large amounts of sodium butyrate given continuously or with multiple daily doses intravenously or by intraperitoneal infusion show that plasma levels achieved are largely under the minimal concentration required to produce pharmacodynamic effects obtained in vitro. These studies suggest that sodium butyrate has a very short half-life by any route of administration. While the half-life of tributyrin is longer than that of butyric acid and sodium butyrate, the absorption kinetics of tributyrin require very large oral doses to reach therapeutic plasma levels (Cmax), which makes effective dosing difficult.
There is limited clinical evidence specifically examining the safety of butyric acid. A comprehensive review found insufficient evidence to guarantee the safety of clinical practice of butyric acid and sodium butyrate, either by anal enema or oral administration of capsule or tablet, concluding that the safety of clinical use should be further evaluated.
Across clinical trials, the reported side effect profile has been mild. Transient mild nausea and headache were reported by 2 patients during the first month of butyrate intervention in a pediatric obesity RCT. Both symptoms disappeared during the following 4 weeks, and no drug therapy was required for their treatment. In a controlled butyrate enema trial for ulcerative colitis, no toxicity was observed in either treatment arm.
Free butyric acid, as a short-chain fatty acid, is naturally volatile and characterized by an unpleasant odor, and is also rapidly absorbed in the gastrointestinal tract. Sodium butyrate is a derivative and sodium salt of butyric acid; it is characterized by greater durability than butyric acid and does not emit the specific smell characteristic of pure butyric acid. These organoleptic properties can affect adherence: adherence to butyrate treatment was lower than placebo in one pediatric trial, with four children refusing to continue after their first doses.
Sodium butyrate, the most common supplemental form, delivers sodium with each dose. In individuals on sodium-restricted diets (e.g., for hypertension or heart failure), the accumulated sodium intake from high-dose supplementation may be clinically relevant and should be factored into overall sodium management.
The clinical trials reviewed used sodium butyrate as an add-on to standard therapy (e.g., mesalamine). Therapeutic success rates were significantly higher in patients receiving BLM add-on therapy versus mesalamine alone (83.3% vs. 47.6%). No pharmacokinetic drugâdrug interactions with mesalamine, immunomodulators, or biologics have been specifically reported in the reviewed literature, but dedicated interaction studies have not been published.
Butyrate's HDAC inhibitory activity is critical for cellular processes including cell growth, differentiation, and apoptosis. Because pharmaceutical HDAC inhibitors are used as oncological drugs (e.g., vorinostat, romidepsin), theoretical additive or potentiating interactions with such agents are biologically plausible. However, no clinical evidence on this interaction has been published in the reviewed sources, and the pharmacological concentrations achieved by oral butyrate supplementation are far lower than those of pharmaceutical HDAC inhibitors.
No studies were identified that compare and contrast the different forms of butyrate supplements in terms of relative bioavailability or clinical effectiveness. The field lacks standardized dosing protocols, long-term safety data beyond 12 weeks in most trials, and direct head-to-head comparisons of sodium butyrate, calcium-magnesium butyrate, and tributyrin formulations in human subjects.
Health conditions that Butyric acid may help support.
Oral sodium butyrate has demonstrated significant reductions in abdominal pain and bloating in clinical studies. Its mechanism involves reducing visceral hypersensitivity, modulating gut motility, and strengthening the intestinal mucosal barrier. Evidence comes primarily from IBS-focused trials.
Butyrate enhances antioxidant defenses in gut mucosa and systemically by upregulating glutathione, catalase, and superoxide dismutase activity, and reducing ROS. Evidence includes human rectal biopsy data from enema trials and animal supplementation studies.
Clinical and preclinical evidence links gut butyrate status to anxiety via the gut-brain axis. A human RCT of a butyrate-generating supplement showed significant improvements in anxiety markers. Reduced SCFA-producing bacteria are consistently found in individuals with anxiety disorders.
Butyrate indirectly modulates appetite through stimulation of GLP-1 and PYY from gut L-cells, which signal satiety. Human evidence links circulating butyrate levels to GLP-1 concentrations, and sodium butyrate supplementation has been shown to raise plasma GLP-1.
Butyrate induces regulatory T-cells (Tregs) via HDAC inhibition at the FoxP3 locus and GPR43 activation, suppressing autoimmune-driven inflammation. Evidence spans multiple autoimmune models including type 1 diabetes, IBD, and pancreatitis.
Butyrate-producing bacteria are reduced in hypertensive patients, and there is a negative correlation between serum butyrate levels and blood pressure. Clinical trials combining butyrate with inulin show reductions in diastolic blood pressure in type 2 diabetic patients.
Multiple human trials indicate that butyrate supplementation can improve fasting glucose, HbA1c, and reduce postprandial glucose excursions. Effects appear more consistent in lean individuals than in those with metabolic syndrome, and mechanisms involve delayed gastric emptying and GLP-1 stimulation.
Butyric acid is the principal energy substrate for colonocytes, providing 60â70% of their energy needs. Beyond the gut, it supports mitochondrial function and energy expenditure in muscle and adipose tissue, as demonstrated in animal studies with strong mechanistic evidence.
Butyrate exerts anti-inflammatory effects by inhibiting histone deacetylases (HDACs), activating GPR109A receptors, and reducing pro-inflammatory cytokines including TNF-α and IL-6. Clinical trials in IBD and related conditions provide human-level evidence for these effects.
Butyrate shows promise as a neuroprotective agent in Alzheimer's disease and age-related cognitive decline via HDAC inhibition, neuroinflammation suppression, mitochondrial support, and blood-brain barrier maintenance. Evidence is primarily preclinical; human clinical trials are in early stages.
Butyric acid (butyrate) is the primary energy substrate for colonocytes and has been investigated as a treatment for ulcerative colitis. Butyrate enemas have been tested in RCTs for distal UC, showing improvement in histological and clinical scores. It inhibits NF-ÎșB, promotes colonocyte proliferation, and supports tight junction integrity.
Butyric acid has documented clinical application in functional constipation, acting via stimulation of intestinal motility and reduction of pain during defecation. PubMed-indexed reviews describe beneficial mechanisms specific to defecation disorders.
Butyric acid (butyrate) is the primary energy source for colonocytes and plays a key role in intestinal barrier integrity and mucosal immune regulation. ConsumerLab.com notes clinical evidence for butyrate supplementation in Crohn's disease. Reduced colonic butyrate production due to gut microbiome dysbiosis is a documented feature of CD pathogenesis.
Preclinical studies demonstrate that sodium butyrate reduces depression-like behaviors via the gut-brain axis, suppressing hippocampal neuroinflammation and neuronal ferroptosis. Human evidence is indirect, linking lower butyrate-producing bacteria to depression diagnoses and supporting a clinical trial in schizophrenia/cognitive disorders.
Butyric acid is used clinically for the treatment and prevention of diarrhea, including antimicrobial-associated and dysbiosis-related forms. It stabilizes the intestinal barrier and modulates microbial composition. Evidence derives from clinical use, case series, and mechanistic research.
Butyrate-producing probiotics (Clostridium butyricum) have been studied in symptomatic uncomplicated diverticular disease (SUDD). Evidence suggests butyrate may reduce chronic mucosal inflammation and symptom burden in diverticular patients through microbiome and barrier modulation.
Butyrate stimulates GLP-1 and PYY secretion from intestinal L-cells, contributing to satiety signaling. Human evidence shows that sodium butyrate supplementation increases plasma GLP-1 concentrations, though direct clinically meaningful appetite suppression from butyrate alone awaits robust RCT confirmation.
Butyric acid is a short-chain fatty acid produced by colonic bacteria fermenting dietary fiber and is a primary energy substrate for colonocytes. It regulates intestinal barrier function, immune modulation, and gene expression, and is central to gut microbiome-host communication. Supplemental butyrate and its prodrug tributyrin are studied for gut microbiome and mucosal health.
Butyric acid is a short-chain fatty acid (SCFA) produced by gut bacterial fermentation of dietary fiber and is a primary mediator of the gut-brain axis. It crosses the blood-brain barrier, influences neuroplasticity, and regulates neurotransmitter synthesis. Tributyrin, its prodrug, has been shown in a clinical study to deliver measurable gut-brain axis benefits for mental well-being.
Animal evidence strongly supports butyrate preventing diet-induced obesity via increased energy expenditure and mitochondrial function. Human evidence is emerging, with a 2026 RCT targeting weight loss with oral sodium butyrate in overweight/obese adults. Lower butyrate is consistently observed in obese individuals.
Clinical evidence supports sodium butyrate supplementation for IBS symptom relief. Placebo-controlled studies show significant reductions in abdominal pain, bloating, and improvements in gut permeability. Butyrate regulates colonocyte function, gut motility, and local immune responses relevant to IBS pathophysiology.
Butyric acid is a short-chain fatty acid (SCFA) that serves as the primary energy source for colonocytes and plays a central role in maintaining intestinal barrier integrity. It has been tested in clinical trials for ulcerative colitis, with evidence supporting mucosal healing and anti-inflammatory effects in IBD.
Butyrate supplementation improves insulin sensitivity in lean/healthy individuals and in mouse models of high-fat diet-induced insulin resistance. Human evidence is strongest in non-obese subjects, while results in metabolic syndrome populations are mixed.
Butyric acid is a short-chain fatty acid and primary fuel for colonocytes that directly strengthens intestinal barrier function. In human intestinal Caco-2 cells, butyrate promotes barrier function by increasing AMPK activity, accelerating tight junction assembly, and inhibiting NF-ÎșB activation. A review in World Journal of Gastroenterology (2011) documented potential beneficial effects of butyrate in intestinal and extra-intestinal diseases including barrier restoration.
Butyrate improves memory in preclinical models via HDAC inhibition, which increases BDNF expression and histone acetylation in the hippocampus. Animal models show rescue of spatial, contextual, and fear memory. Human evidence remains indirect via HDAC inhibitor clinical trials.
Clinical evidence shows that butyrate supplementation influences multiple components of metabolic syndrome including blood pressure, blood sugar, HbA1c, triglycerides, and cholesterol. Results are inconsistent across trials, with some showing benefit and others finding no significant effect.
Body systems that Butyric acid may help support.
Go back